Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$1.52 +1.7%	$1.39	$1.01 ▼ $3.45	$434.85M	1.05	1.59 million shs	317,975 shs
ETNB 89BIO	$10.66 +0.1%	$9.73	$4.16 ▼ $11.84	$1.56B	1.28	1.53 million shs	291,411 shs
JANX Janux Therapeutics	$26.54 -4.4%	$24.60	$22.48 ▼ $71.71	$1.57B	2.86	872,926 shs	260,323 shs
SDGR Schrodinger	$21.80 +0.7%	$21.99	$16.60 ▼ $28.47	$1.61B	1.58	922,709 shs	281,065 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	+3.47%	-1.97%	+9.16%	+28.45%	-53.29%
ETNB 89BIO	+0.19%	-1.21%	+7.14%	+75.74%	+22.70%
JANX Janux Therapeutics	+2.78%	+8.36%	+21.13%	-6.53%	-36.80%
SDGR Schrodinger	+1.88%	-0.28%	+3.69%	-15.92%	-6.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERAS Erasca	2.621 of 5 stars	3.5	2.0	2.2	2.5	0.6
ETNB 89BIO	1.7651 of 5 stars	3.5	1.0	2.1	0.8	0.6
JANX Janux Therapeutics	2.0283 of 5 stars	3.5	1.0	2.5	2.5	0.0
SDGR Schrodinger	1.836 of 5 stars	3.4	1.0	1.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERAS Erasca	3.00	Buy	$4.57	193.98% Upside
ETNB 89BIO	3.00	Buy	$26.43	147.00% Upside
JANX Janux Therapeutics	3.08	Buy	$91.89	241.98% Upside
SDGR Schrodinger	2.75	Moderate Buy	$32.75	48.55% Upside

Current Analyst Ratings Breakdown

Latest ERAS, ETNB, SDGR, and JANX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00
7/12/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/11/2025	JANX Janux Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00
6/27/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/11/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/24/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/14/2025	ERAS Erasca	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$3.00
5/10/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
4/30/2025	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
4/30/2025	ETNB 89BIO	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERAS Erasca	N/A	N/A	N/A	N/A	$1.50 per share	N/A
ETNB 89BIO	N/A	N/A	N/A	N/A	$3.34 per share	N/A
JANX Janux Therapeutics	$10.59M	150.13	N/A	N/A	$19.49 per share	1.38
SDGR Schrodinger	$207.54M	7.79	N/A	N/A	$5.78 per share	3.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERAS Erasca	-$161.65M	-$0.62	N/A	N/A	N/A	N/A	-36.56%	-31.08%	8/11/2025 (Estimated)
ETNB 89BIO	-$367.08M	-$3.38	N/A	N/A	N/A	N/A	-81.44%	-70.17%	8/4/2025 (Estimated)
JANX Janux Therapeutics	-$68.99M	-$1.36	N/A	N/A	N/A	N/A	-9.29%	-8.89%	8/6/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	N/A	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)

Latest ERAS, ETNB, SDGR, and JANX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ERAS Erasca	-$0.12	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	JANX Janux Therapeutics	-$0.50	N/A	N/A	N/A	$0.30 million	N/A
8/4/2025	Q2 2025	ETNB 89BIO	-$0.49	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	SDGR Schrodinger	-$0.83	N/A	N/A	N/A	$52.03 million	N/A
5/13/2025	Q1 2025	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
5/8/2025	Q1 2025	JANX Janux Therapeutics	-$0.43	-$0.38	+$0.05	-$0.38	$0.59 million	N/A
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
5/1/2025	Q1 2025	ETNB 89BIO	-$0.50	-$0.49	+$0.01	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
ETNB 89BIO	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERAS Erasca	N/A	12.35	12.35
ETNB 89BIO	0.06	18.03	18.03
JANX Janux Therapeutics	N/A	58.47	58.47
SDGR Schrodinger	N/A	3.45	3.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERAS Erasca	67.78%
ETNB 89BIO	N/A
JANX Janux Therapeutics	75.39%
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
ERAS Erasca	14.40%
ETNB 89BIO	2.60%
JANX Janux Therapeutics	8.10%
SDGR Schrodinger	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERAS Erasca	120	283.29 million	242.49 million	Optionable
ETNB 89BIO	40	145.98 million	142.19 million	Optionable
JANX Janux Therapeutics	30	59.17 million	54.38 million	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable

ERAS, ETNB, SDGR, and JANX Headlines

Recent News About These Companies

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

2 hours ago | globenewswire.com

Massachusetts Financial Services Co. MA Sells 186,228 Shares of Schrodinger, Inc. (NASDAQ:SDGR)

July 18 at 5:38 AM | marketbeat.com

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

July 17 at 10:30 AM | finance.yahoo.com

Schrodinger (NASDAQ:SDGR) Given New $30.00 Price Target at KeyCorp

July 15 at 4:44 AM | americanbankingnews.com

KeyCorp Has Lowered Expectations for Schrodinger (NASDAQ:SDGR) Stock Price

July 14, 2025 | marketbeat.com

Schrodinger, Inc. (NASDAQ:SDGR) Position Raised by Stephens Investment Management Group LLC

July 13, 2025 | marketbeat.com

BMO Capital Remains a Buy on Schrodinger (SDGR)

July 11, 2025 | theglobeandmail.com

Morgan Stanley Assumes Coverage on Schrödinger (SDGR) Stock

July 10, 2025 | finance.yahoo.com

Allspring Global Investments Holdings LLC Boosts Holdings in Schrodinger, Inc. (NASDAQ:SDGR)

July 7, 2025 | marketbeat.com

SDGR - Schrodinger Inc Ordinary Shares Financials - Morningstar

July 5, 2025 | morningstar.comM

MS initiates coverage on AI Biotechs, flags key pipeline catalysts

July 3, 2025 | investing.com

Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505

July 3, 2025 | msn.com

Morgan Stanley Initiates Coverage on Schrodinger (NASDAQ:SDGR)

July 3, 2025 | marketbeat.com

Schrödinger, Inc. (SDGR) - Yahoo Finance

July 2, 2025 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

July 2, 2025 | prnewswire.com

Short SDGR: Schrödinger bounces from 2024 midpoint, trading range low as potential short-term target

July 1, 2025 | invezz.comI

Sumitomo Mitsui Trust Group Inc. Sells 48,103 Shares of Schrodinger, Inc. (NASDAQ:SDGR)

July 1, 2025 | marketbeat.com

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

June 27, 2025 | tmcnet.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 23, 2025 | globenewswire.com

17,493 Shares in Schrodinger, Inc. (NASDAQ:SDGR) Bought by Palumbo Wealth Management LLC

June 23, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 22, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERAS, ETNB, SDGR, and JANX Company Descriptions

Erasca NASDAQ:ERAS

$1.52 +0.03 (+1.68%)

As of 12:21 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

89BIO NASDAQ:ETNB

$10.66 +0.01 (+0.09%)

As of 12:21 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Janux Therapeutics NASDAQ:JANX

$26.54 -1.22 (-4.38%)

As of 12:22 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Schrodinger NASDAQ:SDGR

$21.80 +0.15 (+0.68%)

As of 12:22 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time